中华肝脏病杂志
中華肝髒病雜誌
중화간장병잡지
CHINESE JOURNAL OF HEPATOLOGY
2015年
1期
34-39
,共6页
贾妮娜%林兰意%郭斯敏%赵钢德%汤伟亮%谢青
賈妮娜%林蘭意%郭斯敏%趙鋼德%湯偉亮%謝青
가니나%림란의%곽사민%조강덕%탕위량%사청
肝炎病毒,乙型%干扰素类%浆样树突状细胞%Toll样受体9
肝炎病毒,乙型%榦擾素類%漿樣樹突狀細胞%Toll樣受體9
간염병독,을형%간우소류%장양수돌상세포%Toll양수체9
Hepatitis B virus%Interferons%Plasmacytoid dendritic cell%Toll-like receptor 9
目的 观察长效干扰素(PEG-IFN α-2a)治疗慢性乙型肝炎过程中外周血浆样树突状细胞(pDC)亚群的变化及其与临床疗效的关系. 方法 41例慢性乙型肝炎患者接受PEG-IFN α-2a(180 μg)每周皮下注射一次,治疗48周;治疗过程中检测肝功能、血清HBV病毒学标志物和HBVDNA,在治疗前及治疗开始后2、12、24、36、48周分别检测外周血pDC数量和功能及Toll样受体(TLR)9的表达水平、血清肿瘤坏死因子(TNF)α及IFN γ水平.对数据进行成组设计t检验、非参数检验、重复测量资料的方差分析. 结果 应答组与无应答组比较,TLR9平均荧光强度、pDC数量及INF α分泌能力在治疗2周时均明显下降,应答组在12周时TLR9平均荧光强度恢复(66.25±13.10),无应答组仍处于低水平(51.47±16.85),差异有统计学意义(t=2.478,P＜0.05);12周时应答组pDC数量恢复(5.24±1.61),无应答组为(3.74±1.25),差异有统计学意义(t=2.644,P＜0.05);12周时应答组IFN α分泌能力明显升高(459.94±200.27) pg/ml,显著高于无应答组[(237.18± 123.57)pg/ml],差异有统计学意义(t=2.942,P＜0.05).治疗24周时,应答组血清IFN γ水平明显升高[(67.81±16.64) pg/ml],显著高于无应答组[(43.73± 15.97) pg/ml],差异有统计学意义(t=3.396,P＜ 0.05);TNFα水平为[(268.94±64.32)pg/ml],也显著高于无应答组[(206.45±78.28) pg/ml],差异有统计学意义(t=2.22,P＜0.05).结论 pDC在PEG-IFNα-2a治疗诱发的早期免疫应答中发挥重要作用,抗病毒治疗过程中pDC数量和功能的恢复可能是机体抗病毒治疗应答的重要因素.
目的 觀察長效榦擾素(PEG-IFN α-2a)治療慢性乙型肝炎過程中外週血漿樣樹突狀細胞(pDC)亞群的變化及其與臨床療效的關繫. 方法 41例慢性乙型肝炎患者接受PEG-IFN α-2a(180 μg)每週皮下註射一次,治療48週;治療過程中檢測肝功能、血清HBV病毒學標誌物和HBVDNA,在治療前及治療開始後2、12、24、36、48週分彆檢測外週血pDC數量和功能及Toll樣受體(TLR)9的錶達水平、血清腫瘤壞死因子(TNF)α及IFN γ水平.對數據進行成組設計t檢驗、非參數檢驗、重複測量資料的方差分析. 結果 應答組與無應答組比較,TLR9平均熒光彊度、pDC數量及INF α分泌能力在治療2週時均明顯下降,應答組在12週時TLR9平均熒光彊度恢複(66.25±13.10),無應答組仍處于低水平(51.47±16.85),差異有統計學意義(t=2.478,P＜0.05);12週時應答組pDC數量恢複(5.24±1.61),無應答組為(3.74±1.25),差異有統計學意義(t=2.644,P＜0.05);12週時應答組IFN α分泌能力明顯升高(459.94±200.27) pg/ml,顯著高于無應答組[(237.18± 123.57)pg/ml],差異有統計學意義(t=2.942,P＜0.05).治療24週時,應答組血清IFN γ水平明顯升高[(67.81±16.64) pg/ml],顯著高于無應答組[(43.73± 15.97) pg/ml],差異有統計學意義(t=3.396,P＜ 0.05);TNFα水平為[(268.94±64.32)pg/ml],也顯著高于無應答組[(206.45±78.28) pg/ml],差異有統計學意義(t=2.22,P＜0.05).結論 pDC在PEG-IFNα-2a治療誘髮的早期免疫應答中髮揮重要作用,抗病毒治療過程中pDC數量和功能的恢複可能是機體抗病毒治療應答的重要因素.
목적 관찰장효간우소(PEG-IFN α-2a)치료만성을형간염과정중외주혈장양수돌상세포(pDC)아군적변화급기여림상료효적관계. 방법 41례만성을형간염환자접수PEG-IFN α-2a(180 μg)매주피하주사일차,치료48주;치료과정중검측간공능、혈청HBV병독학표지물화HBVDNA,재치료전급치료개시후2、12、24、36、48주분별검측외주혈pDC수량화공능급Toll양수체(TLR)9적표체수평、혈청종류배사인자(TNF)α급IFN γ수평.대수거진행성조설계t검험、비삼수검험、중복측량자료적방차분석. 결과 응답조여무응답조비교,TLR9평균형광강도、pDC수량급INF α분비능력재치료2주시균명현하강,응답조재12주시TLR9평균형광강도회복(66.25±13.10),무응답조잉처우저수평(51.47±16.85),차이유통계학의의(t=2.478,P＜0.05);12주시응답조pDC수량회복(5.24±1.61),무응답조위(3.74±1.25),차이유통계학의의(t=2.644,P＜0.05);12주시응답조IFN α분비능력명현승고(459.94±200.27) pg/ml,현저고우무응답조[(237.18± 123.57)pg/ml],차이유통계학의의(t=2.942,P＜0.05).치료24주시,응답조혈청IFN γ수평명현승고[(67.81±16.64) pg/ml],현저고우무응답조[(43.73± 15.97) pg/ml],차이유통계학의의(t=3.396,P＜ 0.05);TNFα수평위[(268.94±64.32)pg/ml],야현저고우무응답조[(206.45±78.28) pg/ml],차이유통계학의의(t=2.22,P＜0.05).결론 pDC재PEG-IFNα-2a치료유발적조기면역응답중발휘중요작용,항병독치료과정중pDC수량화공능적회복가능시궤체항병독치료응답적중요인소.
Objective To investigate the changes in circulating plasmacytoid dendritic cells (pDCs) in patients with chronic hepatitis B (CHB) during the course of treatment with pegylated-intefferon alfa-2s (peg-IFNα-2a) and to determine the correlations with therapeutic response.Methods Forty-one patients with CHB who were receiving peg-IFNα-2a antiviral treatment for 48 weeks were enrolled in the study.Expression of the Toll-like receptor 9 (TLR9) on and frequency and functionality of the pDCs were analyzed at treatment weeks 0,2,12,24,36 and 48.Results All patients exhibited an initially rapid decrease in the numbers of circulating pDCs and showed CpG-induced endogenous IFNα production within the first 2 weeks of treatment.Subsequently,all responders displayed a continuous increase in pDC numbers as well as functionality,both of which peaked around week 12 of treatment; in addition,these treatment responses were accompanied by significantly increased levels of type 1 T helper cytokines (P ＜ 0.05),which did not occur in the non-responders.Conclusion pDCs are involved in the initial therapeutic immune response stimulated by peg-IFNα-2a treatment.Recovery of blood pDC number and functionality may represent a predictor of favorable response to peg-IFNα-2a antiviral treatment in patients with CHB.
